

**AKUH OUTPATIENTS, PRECENT SENSITIVE (number of isolates tested) JAN TO JUNE 2022**

Organism	AMK	AMP	AMC	ATM	CFM	CIP	CRO	CT*	CXM	GEN	IPM	MEM	SXT	TZP	NIT†	ETP
<i>E.coli</i>	97 (8638)	12 (8642)	53 (8640)	30 (867)	24 (8364)	32 (8376)	27 (8640)	0 (774)	10 (1037)	75 (8638)	68(1884)	63(1515)	34 (8640)	77 (8631)	32 (8376)	91(7998)
<i>Enterobacter</i> spp	85 (437)	-	-	43(192)	37(367)	59(371)	44(440)	0(130)	06(235)	71(440)	59(275)	56(229)	57(429)	68(431)	-	81(257)
<i>Klebsiella</i> spp	78(2645)	-	51(2625)	33(661)	39(2323)	57(2333)	41(2644)	0(725)	20(907)	73(2647)	51(1282)	41(1007)	54(2624)	65(2626)	-	79(2049)
<i>Serratia</i> spp	40 (396)	-	-	20 (253)	22 (354)	26 (360)	25 (396)	-	-	29 (395)	28(300)	31(322)	38(391)	28(279)	-	-
<i>Proteus mirabilis</i>	84 (437)	23 (436)	53 (435)	68 (121)	45 (374)	47 (372)	53 (433)	-	27 (164)	57 (436)	-	96(208)	25 (435)	-	-	89(298)
	AMK	ATM	CAZ	CIP	CT*	GEN	LEV	IMP	MEM	SXT	TET	MINO	TIG	TZP	TOB	
<i>Acinetobacter</i> spp	54 (1085)	-	36 (1015)	38 (1030)	0 (685)	54 (1086)	-	38 (915)	37 (954)	44 (1082)	23 (99)	83 (277)	25 (204)	39 (1010)	65 (621)	
<i>P.aeruginosa</i>	80 (2711)	58 (2154)	78 (2698)	66 (2704)	0 (580)	74 (2711)	-	78 (2703)	77 (2714)	-	-	-	-	80 (2704)	77 (1711)	
<i>S.maltophilia</i>	-	-	-	-	-	-	93 (178)	-	-	97 (180)	-	99 (175)	-	-	-	
<i>B.cepacia</i>	-	-	87 (609)	-	-	-	57 (582)	-	57 (607)	-	-	84 (77)	-	--	-	
	AMP	CLR	CLI	ERY	FD	CIP/LEV	LNZ	TET	SXT	PEN	OX	VAN				
<i>Enterococcus</i> spp	74 (2060)	82 (500)	-	-	-	-	98 (545)	-	-	-	-	92 (2059)				
<i>S.aureus</i>	-	97 (772)	76 (2488)	37 (2489)	79 (2489)	26 (2680)	100 (827)	66 (2628)	61 (2697)	0.8 (1499)	33 (2711)	100 (1896)				
CONS																

\*Current susceptibility testing guidelines suggest no 'sensitive' category for colistin. Isolates are either intermediate or resistant. Percent resistance rates for colistin are: *Acinetobacter* 3.6%; *E.coli* 1.4%; *Klebsiella* spp 11%; *Enterobacter* spp 7.7%; and 0.7% for *P.aeruginosa* in 2022.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

**Abbreviations:** AMK–Amikacin; AMP–Ampicillin; ATM–Aztreonam; AMC–Amoxicillin/Clavulanate; AZM–Azithromycin; BDQ–Bedaquiline; CAS–Caspofungin; CAZ–Ceftazidime; CFM–Cefixime; CFZ–Clofazimine; CIP–Ciprofloxacin; CLI–Clindamycin; CLA–Clarithromycin; CLR–Chloramphenicol; CONS– Coagulase negative staphylococci; CRO–Ceftriaxone; CXM–Cefuroxime; CT–Colistin; ERY–Erythromycin; ETHM–Ethambutol; FLUC–Fluconazole; INH–Isoniazid; FD–Fusidic acid; GEN–Gentamicin; IPM–Imipenem; LEV–Levofloxacin; LNZ–Linezolid; MOX–Moxifloxacin; MTZ–Metronidazole; MEM–Meropenem; MINO–Minocycline; NIT–Nitrofurantoin; OX–Oxacillin; OFX–Ofloxacin; PEN–Penicillin; PZA–Pyrazinamide; RIF–Rifampicin; SXT–Co-trimoxazole; TET–Tetracycline; TIG–Tigecycline; TZP–Piperacillin/Tazobactam; TOB –Tobramycin; VAN–Vancomycin; VOR–Voriconazole



Aga Khan University Hospital  
Clinical Laboratory  
Microbiology  
ANTIBIOTIC SUSCEPTIBILITY REPORT  
Jan-Jun 2022  
Telephone:34930051 ext.1608,1682

**AKUH OUT PATIENTS, PRECENT SENSITIVE (number of isolates tested) Jan-Jun 2022**

Organism	AMP	ATM	AZM	CAZ	CFM	CIP	CLR	CRO	CXM	ERY	MEM/ IPM	SXT	TET
<i>Campylobacter jejuni/coli</i>	-	-	-	-	-	4(68)	-	-	-	81(68)	-	-	59 (68)
<i>Salmonella</i> Paratyphi A	94(254)	-	-	-	100(254)	0.4(254)	99(252)	100(254)	-	-	-	99(254)	-
<i>Salmonella</i> Typhi	17(2257)	-	100(2245)	-	28(2255)	0.5(2246)	19(2250)	28(2257)	-	-	100(2247)	20(2257)	-
<i>Shigella</i> spp	14(36)	-	-	-	22(35)	40(35)	83(36)	22(36)	-	-	100(33)	28(36)	-
<i>Vibrio cholerae</i>	11 (163)	-	-	-	-	97 (164)	88 (161)	-	-	-	-	57(164)	99 (161)
		<b>AMC</b>	<b>CIP</b>	<b>CFM</b>	<b>CLR</b>	<b>CRO</b>	<b>CXM</b>	<b>ERY</b>	<b>SXT</b>	<b>TET</b>	<b>PEN</b>	<b>AZM</b>	
<i>Haemophilus influenzae</i>	90(220)	99(220)	63(219)	-	90(220)	100 (220)	92 (100)	-	27(220)	82(220)	-	-	
<i>Moraxella catarrhalis</i>	-	100(35)	51(35)	-	100(34)	100 (35)	3 (35)	94(35)	71(35)	100(34)	-	-	
<i>Neisseria gonorrhoeae</i>	-	-	4(63)	100(23)	-	100 (23)	-	-	-	9(23)	4(423)	100(23)	
		<b>CLI</b>	<b>CLR</b>	<b>ERY</b>	<b>CXM</b>	<b>LEV/OFX</b>	<b>CRO</b>	<b>PEN</b>	<b>SXT</b>	<b>TET</b>	<b>VAN</b>		
<i>Streptococcus pyogenes(GAS)</i>	51 (138)	78(138)	-.*	-	71(83)	100 (140)	100 (139)	-	-	100 (140)			
<i>Streptococcus agalactiae(GBS)</i>	50(441)	81(445)	-.*	-	60 (699)	100 (458)	100 (857)	-	-	100 (159)			
<i>Streptococcus pneumoniae*</i>	95(161)	96(182)	34(165)	80(153)	93(152)	99 (180)	36 (177)	15(162)	29 (157)	100 (179)			
		<b>MTZ</b>	<b>AMC</b>										
<i>Bacteroides</i> spp	20(60)	33(3)											
<i>Clostridium</i> spp	58(12)	100(02)											
		<b>INH</b>	<b>RIF</b>	<b>PZA</b>	<b>ETHM</b>	<b>LEV</b>	<b>MOX</b>	<b>BDQ</b>	<b>CFZ</b>	<b>LNZ</b>			
<i>Mycobacterium tuberculosis</i>	85(530)	93(530)	92(530)	92(530)	84(530)	89(45)	88(45)	100(45)	96(45)				
		<b>AMC</b>	<b>AMK</b>	<b>CLA</b>	<b>IPM</b>	<b>CIP</b>	<b>SXT</b>	<b>MOX</b>					
<i>Nocardia</i> spp	13(23)	100(23)	04(23)	26(23)	22(23)	96(23)	45(23)						
		<b>FLU</b>	<b>VOR</b>	<b>CAS</b>									
<i>Candida albicans</i>	98(114)	98(114)	100(113)										
		<b>FLU</b>	<b>VOR</b>	<b>CAS</b>									
<i>Non-albicans Candida</i> spp	77(288)	99(203)	100(259)										

\*Susceptibility data includes meningitic and non-meningitic isolates. Penicillin susceptibility suggests susceptibility to amoxicillin and ampicillin for treatment of pneumonia cases, as well as to Penicillin G for treatment of meningitis.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

\* Due to data inconsistencies, antibiogram analysis not performed; results will be available for Jun-Dec 2022 antibiogram.

**Abbreviations:** AMK–Amikacin; AMP–Ampicillin; ATM–Aztreonam; AMC–Amoxicillin/Clavulanate; AZM–Azithromycin; BDQ–Bedaquiline; CAS–Caspofungin; CAZ–Ceftazidime; CFM–Cefixime; CFZ–Clofazimine; CIP–Ciprofloxacin; CLI–Clindamycin; CLA–Clarithromycin; CLR–Chloramphenicol; CONS–Coagulase negative staphylococci; CRO–Ceftriaxone; CXM–Cefuroxime; CT–Colistin; ERY–Erythromycin; ETHM–Ethambutol; FLUC–Fluconazole; INH–Isoniazid; FD–Fusidic acid; GEN–Gentamicin; IPM–Imipenem; LEV–Levofloxacin; LNZ–Linezolid; MOX–Moxifloxacin; MTZ–Metronidazole; MEM–Meropenem; MINO–Minoocycline; NIT–Nitrofurantoin; OX–Oxacillin; OFX–Ofloxacin; PEN–Penicillin; PZA–Pyrazinamide; RIF–Rifampicin; SXT–Co-trimoxazole; TET–Tetracycline; TIG–Tigecycline; TZIP–Piperacillin/Tazobactam; TOB–Tobramycin; VAN–Vancomycin; VOR–Voriconazole



Aga Khan University Hospital  
Clinical Laboratory  
Microbiology  
**ANTIBIOTIC SUSCEPTIBILITY REPORT**  
Jan-June 2022  
Telephone:34930051 ext.1608,1682

**AKUH OUT PATIENTS. PRECENT SENSITIVE (number of isolates tested) Jun-Dec 2022**

Organism	AMP	ATM	AZM	CAZ	CFM	CIP	CLR	CRO	CXM	ERY	MEM/ IPM	SXT	TET
<i>Campylobacter jejuni/coli</i>	-	-	-	-	-	7.4(54)	-	-	-	77.8(54)	-	-	63(54)
<i>Salmonella Paratyphi A</i>	96.3(484)	-	-	-	100(484)	0.4(484)	99.6(481)	100(484)	-	-	-	99.6(484)	-
<i>Salmonella Typhi</i>	20.6(3947)	-	100(3927)	-	30.4 (3945)	0.2 (3949)	18.3 (3936)	30.7 (3947)	-	-	100 (3932)	18.8 (3945)	-
<i>Shigella spp</i>	20(70)	-	-	-	27(69)	50.7(69)	91.3(69)	27.1(70)	-	-	100(68)	25.7(70)	-
<i>Vibrio cholerae</i>	5 (80)	-	-	-	-	95 (80)	65.4 (78)	-	-	-	-	43.6 (80)	97.5 (79)
	AMP	AMC	CIP	CFM	CLR	CRO	CXM	ERY	SXT	TET	PEN	AZM	
<i>Haemophilus influenzae</i>	91.6(239)	99.2(239)	62.1(240)	-	90.4(239)	99.6(239)	93.8(240)	-	22.6 (239)	81.4(236)	-	-	
<i>Moraxella catarrhalis</i>	-	91.5(47)	40.4(47)	-	93.6(47)	100(47)	0 (47)	78.7(47)	60.9(46)	86.7(45)	-	-	
<i>Neisseria gonorrhoeae</i>	-	-	0(15)	100(15)	-	100(15)	-	-	-	6.7(15)	0(15)	100(15)	
	CLI	CLR	ERY	CXM	LEV/OFX	CRO	PEN	SXT	TET	VAN			
<i>Streptococcus pyogenes(GAS)</i>	49.3(345)	77.6(343)	49.3 (152)	-	86.5(347)	100(348)	100(346)	-	-	100(140)			
<i>Streptococcus agalactiae(GBS)</i>	49.9(515)	82.3(339)	40.6 (32)	-	66.6 (1063)	100(1069)	100(1039)	-	-	100(859)			
<i>Streptococcus pneumoniae*</i>	64(150)	94.8(153)	34(150)	86.2(87)	94.5(145)	98.1(157)	27(159)	15.9(145)	32.6 (138)	100(155)			
	MTZ	AMC											
<i>Bacteroides spp</i>	51.6(128)	57.8(83)											
<i>Clostridium spp</i>	74.1(27)	100(23)											
	INH	RIF	PZA	ETHM	LEV	MOX	BDQ	CFZ	LNZ				
<i>Mycobacterium tuberculosis</i>	84(521)	94.6(521)	96.2(521)	95.5(244)	80.4(521)	93.3(45)	93.3(45)	91.1(45)	93.3(45)				
	AMC	AMK	CLA	IPM	SXT	MOX							
<i>Nocardia spp</i>	15.6(45)	95.7(46)	11.4(44)	21.3(47)	19.6(46)	82.6(46)	37.8(45)						
	FLU	VOR	CAS										
<i>Candida albicans</i>	98(150)	98(150)	100(147)										
	FLU	VOR	CAS										
<i>Non-albicans Candida spp</i>	85.1(463)	98.1(373)	100(443)										

\*Susceptibility data includes meningitic and non-meningitic isolates. Penicillin susceptibility suggests susceptibility to amoxicillin and ampicillin for treatment of pneumonia cases, as well as to Penicillin G for treatment of meningitis.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

**Abbreviations:** AMK–Amikacin; AMP–Ampicillin; ATM–Aztreonam; AMC–Amoxicillin/Clavulanate; AZM–Azithromycin; BDQ–Bedaquiline; CAS–Casposungin; CAZ–Ceftazidime; CFM–Cefixime; CFZ–Cefazolin; CIP–Ciprofloxacin; CLI–Clindamycin; CLA–Clarithromycin; CLR–Chloramphenicol; CONS–Coagulase negative staphylococci; CRO–Ceftriaxone; CXM–Cefuroxime; CT–Colistin; ERY–Erythromycin; ETHM–Ethambutol; FLUC–Fluconazole; INH–Isoniazid; FD–Fusidic acid; GEN–Gentamicin; IPM–Imipenem; LEV–Levofloxacin; LNZ–Linezolid; MOX–Moxifloxacin; MTZ–Metronidazole; MEM–Meropenem; MINO–Minocycline; NIT–Nitrofurantoin; OX–Oxacillin; OFX–Ofloxacin; PEN–Penicillin; PZA–Pyrazinamide; RIF–Rifampicin; SXT–Cotrimoxazole; TET–Tetracycline; TIG–Tigecycline; TZP–Piperacillin/Tazobactam; TOB–Tobramycin; VAN–Vancomycin; VOR–Voriconazole



Aga Khan University Hospital  
Clinical Laboratory  
Microbiology  
**ANTIBIOTIC SUSCEPTIBILITY REPORT**  
Jun-Dec2022  
Telephone:34930051 ext.1608,1682

**AKUH OUTPATIENTS. PRECENT SENSITIVE (number of isolates tested) JUNE TO DEC 2022**

Organism	AMK	AMP	AMC	ATM	CFM	CIP	CRO	CT*	CXM	GEN	IPM	MEM	SXT	TZP	NIT†	ETP
<i>E.coli</i>	96.3 (10759)	12.3 (10760)	50.7 (10757)	31.2 (1232)	23.2 (10550)	31.2 (10588)	26.9 (10751)	0 (1107)	11 (1387)	76.2 (10758)	59.6 (2230)	58.4 (2097)	33.4 (10736)	74.9 (10732)	-	90.5 (9734)
<i>Enterobacter</i> spp	85 (758)	-	-	39.8 (397)	43.9 (496)	56.4 (707)	47.5 (755)	0 (217)	8.9 (424)	69.7 (756)	60.5 (458)	60.2 (438)	56.6 (746)	65.5 (747)	-	81 (257)
<i>Klebsiella</i> spp	80 (3771)	-	53.2 (3755)	38.6 (1317)	41.8 (3573)	57.3 (3593)	44.9 (3765)	0 (925)	21.6 (1456)	74.5 (3765)	56 (1851)	54.9 (1730)	54.7 (3748)	67.5 (3755)	-	81.6 (2502)
<i>Serratia</i> spp	29.3 (696)	-	-	13.8 (556)	14.2 (663)	18.8 (668)	18.1 (691)	-	-	21.9 (695)	17.5 (550)	17.8 (607)	39.8 (689)	16.1 (576)	-	-
<i>Proteus</i> <i>mirabilis</i>	86.8 (636)	25.6 (637)	54.6 (634)	73.4 (259)	45.8 (602)	44.7 (608)	55.9 (634)	-	25.7 (284)	61.7 (634)	-	94.3 (298)	26.4 (629)	-	-	91.2 (373)
	AMK	ATM	CAZ	CIP	CT*	GEN	LEV	IMP	MEM	SXT	TET	MINO	TIG	TZP	TOB	
<i>Acinetobacter</i> spp	55.5 (1441)	-	38.2 (1373)	40.4 (1383)	0 (847)	57.9 (1440)	-	38.2 (1214)	37.5 (1260)	44.4 (1433)	18 (59)	88.2 (313)	22.4 (304)	40.9 (1345)	58 (628)	
<i>P.aeruginosa</i>	77.3 (3988)	59.3 (3558)	77 (3972)	65.3 (3967)	0 (998)	72.3 (3990)	-	76.6 (3963)	75 (3981)	-	-	-	-	78 (3963)	74.9 (1678)	
<i>S.maltophilia</i>	-	-	-	-	-	-	92.9 (295)	-	-	97 (300)	-	98.1 (269)	-	-	-	
<i>B.cepacia</i>	-	-	83.4 (949)	-	-	-	60.6 (749)	-	57.2 (947)	-	-	67.7 (96)	-	--	-	
	AMP	CLR	CLI	ERY	FD	CIP/LEV	LNZ	TET	SXT	PEN	OX	VAN				
<i>Enterococcus</i> spp	74.2 (2454)	79.9 (692)	-	-	-	-	98.9 (637)	-	-	-	-	92.7 (2452)				
<i>S.aureus</i>	-	96.1 (1067)	75.3 (3610)	35.4 (3609)	79.6 (3610)	24.8 (3831)	100 (1421)	66.4 (723)	64.3 (3868)	0.5 (1830)	30.4 (3881)	100 (2808)				
CONS																

\*Current susceptibility testing guidelines suggest no 'sensitive' category for colistin. Isolates are either intermediate or resistant. Percent resistance rates for colistin are: *Acinetobacter* 4.6 %; *E.coli* 1.9%; *Klebsiella* spp 14%; *Enterobacter* spp 13.4%; and 0.5% for *P.aeruginosa* in 2022.

**Note:** Susceptibility profiles are derived from all specimens received by the Clinical Microbiology Laboratory. Antibiotic susceptibilities of bacteria recovered from specific wards or populations may differ.

**Abbreviations:** AMK–Amikacin; AMP–Ampicillin; ATM–Aztreonam; AMC–Amoxicillin/Clavulanate; AZM–Azithromycin; BDQ–Bedaquiline; CAS–Casopfungin; CAZ–Ceftazidime; CFM–Cefixime; CFZ–Ceftriaxone; CIP–Ciprofloxacin; CLI–Clindamycin; CLA–Clarithromycin; CLR–Chloramphenicol; CONS–Coagulase negative staphylococci; CRO–Ceftriaxone; CXM–Cefuroxime; CT–Colistin; ERY–Erythromycin; ETHM–Ethambutol; FLUC–Fluconazole; INH–Isoniazid; FD–Fusidic acid; GEN–Gentamicin; IPM–Imipenem; LEV–Levofloxacin; LNZ–Linezolid; MOX–Moxifloxacin; MTZ–Metronidazole; MEM–Meropenem; MINO–Minocycline; NIT–Nitrofurantoin; OX–Oxacillin; OFX–Ofloxacin; PEN–Penicillin; PZA–Pyrazinamide; RIF–Rifampicin; SXT–Co-trimoxazole; TET–Tetracycline; TIG–Tigecycline; TZP–Piperacillin/Tazobactam; TOB–Tobramycin; VAN–Vancomycin; VOR–Voriconazole



Aga Khan University Hospital  
Clinical Laboratory  
Microbiology  
ANTIBIOTIC SUSCEPTIBILITY REPORT  
June-Dec2022  
Telephone:34930051 ext.1608,1682